loading

Larimar Therapeutics Inc Stock (LRMR) Latest News

pulisher
Nov 21, 2024

Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MyChesCo

Nov 21, 2024
pulisher
Nov 20, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Larimar Therapeutics (NASDAQ:LRMR) Given Outperform Rating at William Blair - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics Presents Additional Data from Phase 1 - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Reports Promising Clinical Data for Friedreich's Ataxia Treatment Nomlabofusp | LRMR Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Buy" from Analysts - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

(LRMR) Trading Signals - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 16, 2024

Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey

Nov 16, 2024
pulisher
Nov 15, 2024

Blue Owl Capital Holdings LP Increases Stake in Larimar Therapeu - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey

Nov 14, 2024
pulisher
Nov 14, 2024

Janus Henderson's Strategic Acquisition in Larimar Therapeutics - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Verition Fund Management LLC Reduces Stake in Larimar Therapeuti - GuruFocus.com

Nov 14, 2024
pulisher
Nov 11, 2024

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart

Nov 11, 2024
pulisher
Nov 08, 2024

PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online

Nov 08, 2024
pulisher
Nov 06, 2024

Goldman Sachs Group Inc's Strategic Acquisition in Larimar Thera - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

When (LRMR) Moves Investors should Listen - Stock Traders Daily

Nov 06, 2024
pulisher
Nov 04, 2024

Research Analysts Offer Predictions for LRMR FY2024 Earnings - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

What is HC Wainwright's Estimate for LRMR FY2024 Earnings? - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

HC Wainwright Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR) - Defense World

Nov 02, 2024
pulisher
Nov 02, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Larimar Therapeutics Inc Reports Q3 2024 Net Loss of $15.5 Milli - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

After A 140% Surge In Feb., LRMR Has Given Back Its GainsCan Upcoming FA Data Spark A Comeback? - RTTNews

Nov 01, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics (NASDAQ:LRMR) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics' (LRMR) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics Q3 2024 Financial Update - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Larimar: Q3 Earnings Snapshot - CTPost

Oct 30, 2024
pulisher
Oct 30, 2024

Larimar Therapeutics (NASDAQ:LRMR) Shares Gap UpHere's Why - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 30, 2024
pulisher
Oct 30, 2024

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire

Oct 30, 2024
pulisher
Oct 26, 2024

(LRMR) Investment Analysis and Advice - Stock Traders Daily

Oct 26, 2024
pulisher
Oct 24, 2024

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Larimar Therapeutics (NASDAQ:LRMR) Trading Up 6.8%Here's Why - MarketBeat

Oct 24, 2024
pulisher
Oct 20, 2024

Larimar Therapeutics (NASDAQ:LRMR) Now Covered by Analysts at Oppenheimer - Defense World

Oct 20, 2024
pulisher
Oct 17, 2024

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

Larimar initiated with bullish view at Oppenheimer on lead drug - MSN

Oct 16, 2024
pulisher
Oct 16, 2024

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Benzinga

Oct 16, 2024
pulisher
Oct 16, 2024

Larimar stock gets bullish view at Oppenheimer (LRMR:NASDAQ) - Seeking Alpha

Oct 16, 2024
pulisher
Oct 16, 2024

Oppenheimer Begins Coverage on Larimar Therapeutics (NASDAQ:LRMR) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

(LRMR) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 10, 2024

Millennium Management LLC Boosts Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Larimar Therapeutics Inc (LRMR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

An Analysis of Larimar Therapeutics Inc (LRMR)’s Potential Price Growth - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Larimar Therapeutics Inc (LRMR) Stock: A Year of Highs and Lows - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Hopeful Week For Insiders Who Bought US$540.7k Of Larimar Therapeutics Stock - Simply Wall St

Oct 09, 2024
pulisher
Oct 07, 2024

Technical analysis of Larimar Therapeutics Inc (LRMR) stock chart patterns - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Financial Metrics Unveiled: Larimar Therapeutics Inc (LRMR)’s Key Ratios in the Spotlight - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

Analysts Offer Predictions for Larimar Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:LRMR) - MarketBeat

Oct 07, 2024
$18.94
price down icon 1.35%
$75.45
price up icon 0.87%
$43.39
price up icon 3.19%
$378.13
price up icon 0.30%
$206.16
price up icon 7.31%
$120.72
price up icon 1.84%
Cap:     |  Volume (24h):